Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas.

Shen F, Zhang Y, Yao Y, Hua W, Zhang HS, Wu JS, Zhong P, Zhou LF.

Neurosurg Rev. 2014 Jul;37(3):367-80; discussion 380. doi: 10.1007/s10143-014-0539-5. Epub 2014 May 1. Review.

PMID:
24781189
2.

Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma.

Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zöllner H, Schmiegel W, Hahn S, Schroers R.

Neuro Oncol. 2012 Jan;14(1):29-33. doi: 10.1093/neuonc/nor169. Epub 2011 Sep 21.

PMID:
21937590
3.

GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients.

Nakamizo S, Sasayama T, Shinohara M, Irino Y, Nishiumi S, Nishihara M, Tanaka H, Tanaka K, Mizukawa K, Itoh T, Taniguchi M, Hosoda K, Yoshida M, Kohmura E.

J Neurooncol. 2013 May;113(1):65-74. doi: 10.1007/s11060-013-1090-x. Epub 2013 Mar 1.

PMID:
23456655
4.

[Establishment of diagnostic model of cerebrospinal protein fingerprint pattern for glioma and its clinical application].

Liu J, Zheng S, Yu JK, Yu XB, Liu WG, Zhang JM, Hu X.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2005 Mar;34(2):141-7. Chinese.

PMID:
15812888
5.

Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma.

Kuratsu J, Yoshizato K, Yoshimura T, Leonard EJ, Takeshima H, Ushio Y.

J Natl Cancer Inst. 1993 Nov 17;85(22):1836-9.

PMID:
8230263
6.

Proteomics of gliomas: initial biomarker discovery and evolution of technology.

Kalinina J, Peng J, Ritchie JC, Van Meir EG.

Neuro Oncol. 2011 Sep;13(9):926-42. doi: 10.1093/neuonc/nor078. Review.

PMID:
21852429
7.

Cerebrospinal fluid sterols in the evaluation of patients with gliomas.

Ransohoff J, Weiss J.

Natl Cancer Inst Monogr. 1977 Dec;46:119-24.

PMID:
613222
8.

Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).

Sasayama T, Nakamizo S, Nishihara M, Kawamura A, Tanaka H, Mizukawa K, Miyake S, Taniguchi M, Hosoda K, Kohmura E.

Neuro Oncol. 2012 Mar;14(3):368-80. doi: 10.1093/neuonc/nor203. Epub 2011 Dec 12.

PMID:
22156547
9.

Circulating microRNA biomarkers for glioma and predicting response to therapy.

Tumilson CA, Lea RW, Alder JE, Shaw L.

Mol Neurobiol. 2014 Oct;50(2):545-58. doi: 10.1007/s12035-014-8679-8. Epub 2014 Apr 3. Review.

PMID:
24696266
10.

Experimental validation of 5 in-silico predicted glioma biomarkers.

Towner RA, Jensen RL, Vaillant B, Colman H, Saunders D, Giles CB, Wren JD.

Neuro Oncol. 2013 Dec;15(12):1625-34. doi: 10.1093/neuonc/not124. Epub 2013 Oct 24.

PMID:
24158112
11.

Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients.

Shi W, Lv C, Qi J, Zhao W, Wu X, Jing R, Wu X, Ju S, Chen J.

J Mol Neurosci. 2012 Mar;46(3):470-5. doi: 10.1007/s12031-011-9617-0. Epub 2011 Sep 1.

PMID:
21881830
12.

Investigation of serum proteome alterations in human glioblastoma multiforme.

Gollapalli K, Ray S, Srivastava R, Renu D, Singh P, Dhali S, Bajpai Dikshit J, Srikanth R, Moiyadi A, Srivastava S.

Proteomics. 2012 Aug;12(14):2378-90. doi: 10.1002/pmic.201200002.

PMID:
22684992
13.

Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma.

Sampath P, Weaver CE, Sungarian A, Cortez S, Alderson L, Stopa EG.

Cancer Control. 2004 May-Jun;11(3):174-80.

PMID:
15153841
14.

Biomarkers of clinical responsiveness in brain tumor patients : progress and potential.

El-Jawahri A, Patel D, Zhang M, Mladkova N, Chakravarti A.

Mol Diagn Ther. 2008;12(4):199-208. Review.

PMID:
18652516
15.

[OMICS and biomarkers of glial tumors].

Idbaih A.

Rev Neurol (Paris). 2011 Oct;167(10):691-8. doi: 10.1016/j.neurol.2011.07.007. Epub 2011 Sep 1. Review. French.

PMID:
21889780
16.

Angiogenic potential of the cerebrospinal fluid (CSF) of patients with high-grade gliomas measured with the chick embryo chorioallantoic membrane assay (CAM).

Sinning M, Letelier R, Rosas C, Fuenzalida M, Lemus D.

Biol Res. 2012;45(2):135-8. doi: 10.4067/S0716-97602012000200005.

PMID:
23096357
17.

Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors.

Zheng PP, Luider TM, Pieters R, Avezaat CJ, van den Bent MJ, Sillevis Smitt PA, Kros JM.

J Neuropathol Exp Neurol. 2003 Aug;62(8):855-62.

PMID:
14503641
18.

Long non-coding RNAs as potential biomarkers and therapeutic targets for gliomas.

Sun Y, Wang Z, Zhou D.

Med Hypotheses. 2013 Aug;81(2):319-21. doi: 10.1016/j.mehy.2013.04.010. Epub 2013 May 18.

PMID:
23688743
19.

Preliminary use of differential scanning calorimetry of cerebrospinal fluid for the diagnosis of glioblastoma multiforme.

Chagovetz AA, Jensen RL, Recht L, Glantz M, Chagovetz AM.

J Neurooncol. 2011 Dec;105(3):499-506. doi: 10.1007/s11060-011-0630-5. Epub 2011 Jul 1.

PMID:
21720810
20.

Towards developing biomarkers for glioblastoma multiforme: a proteomics view.

Jayaram S, Gupta MK, Polisetty RV, Cho WC, Sirdeshmukh R.

Expert Rev Proteomics. 2014 Oct;11(5):621-39. doi: 10.1586/14789450.2014.939634. Epub 2014 Aug 13. Review.

PMID:
25115191

Supplemental Content

Support Center